Scientists found that two experimental drugs have the potential to restore pumping strength to failing hearts by ensuring adrenalin's ability to drive heartbeat strength is maintained, and not thwarted, as it typically is in heart failure patients. When tested in human-like mouse models of heart failure, the therapies were found to slow, and in some cases halt, the progression of the disease.